Underlying technology identified through sponsored research conducted at Georgia Tech Research Institute
Salvus, part of the CJB family of companies in the US, has announced the upcoming commercialization of a novel interferometric platform that provides highly accurate detection of contaminants or pathogens in many industries.
Applicable in human and animal health, agriculture, water quality management, food processing and the chemical and transportation industries, Salvus detection technology features handheld detection in minutes with extreme specificity and at parts per trillion accuracy in many applications.
The platform is proven to detect SARS-CoV-2, the virus that causes COVID-19, with sensitivity and specificity comparable to molecular tests, as well as dozens of other potentially dangerous pathogens and chemical contaminants.
The Salvus detection system consists of a lightweight, handheld analyzer and a disposable cartridge – both patents pending – that is adaptable to many point-of-care and on-site uses ranging from airports and health care facilities to farm fields, tanks, and animal enclosures. Individual cartridges can be developed and manufactured for simultaneous detection of multiple contaminants, chemical or biological, providing fast and precise results.
The underlying technology leading to the Salvus detection device came out of sponsored research conducted originally at the Georgia Tech Research Institute (GTRI) while exploring ways to improve pathogen and contaminant detection throughout the food and agriculture industries.
Salvus technology is competitive with the current gold standard of polymerase chain reaction detection for many human and animal health, agricultural and industrial applications.